Efficacy and safety of combined piroxicam, dexamethasone, orphenadrine, and cyanocobalamin treatment in mandibular molar surgery
Efficacy and safety of combined piroxicam, dexamethasone, orphenadrine, and cyanocobalamin treatment in mandibular molar surgery
复制标题
DOI：
10.1590/s0100-879x2006000900012
复制
发表时间：
2006-09-01
影响因子：
2.3
通讯作者：
Moraes, M.E.A.
中科院分区：
文献类型：
--
作者：
Barroso, A.B.;Lima, V.;Moraes, M.E.A.
第三磨牙拔除是一种常见的手术，经常伴有中度或重度疼痛，并且涉及足够数量的患者，使得研究相对容易进行。本研究的目的是确定 10 mg 吡罗昔康、1 mg 地塞米松、35 mg 枸橼酸奥芬那君和 2.5 mg 氰钴胺 (Rheumazin((R))) 组合治疗与单独使用 20 mg 吡罗昔康 (Feldene((R))) 相比在下颌第三磨牙手术中的疗效和安全性。这项随机双盲研究纳入了 80 名计划拔除第三磨牙的患者。他们在拔牙后 30 分钟接受 (vo) Rheumazin 或 Feldene，每天一次，连续 4 天。疼痛通过视觉模拟量表和逃避镇痛（扑热息痛）的需要来确定。用卷尺评估面部肿胀，并记录不良反应和患者满意度。 Rheumazin 和 Feldene（对照组）之间的面部肿胀没有统计学上的显着差异。两种药物在控制疼痛方面同样有效，Rheumazin 的副作用比 Feldene 更少。因此，风马嗪似乎在下颌磨牙手术中提供了更好的风险/效益比。由于非甾体类抗炎药引起的副作用严重限制了这些药物在临床实践中的常规使用，因此我们的结果表明，风马嗪可能是第三磨牙拔除治疗的良好选择。
Third molar extraction is a common procedure frequently accompanied by moderate or severe pain, and involves sufficient numbers of patients to make studies relatively easy to perform. The aim of the present study was to determine the efficacy and safety of the therapeutic combination of 10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine citrate, and 2.5 mg cyanocobalamin (Rheumazin((R))) when compared with 20 mg piroxicam alone (Feldene((R))) in mandibular third molar surgery. Eighty patients scheduled for removal of the third molar were included in this randomized and double-blind study. They received (vo) Rheumazin or Feldene 30 min after tooth extraction and once daily for 4 consecutive days. Pain was determined by a visual analogue scale and by the need for escape analgesia (paracetamol). Facial swelling was evaluated with a measuring tape and adverse effects and patient satisfaction were recorded. There was no statistically significant difference in facial swelling between Rheumazin and Feldene (control group). Both drugs were equally effective in the control of pain, with Rheumazin displaying less adverse effects than Feldene. Therefore, Rheumazin appears to provide a better risk/ benefit ratio in the mandibular molar surgery. Since the side effects resulting from nonsteroidal anti-inflammatory drug administration are a severe limitation to the routine use of these drugs in clinical practice, our results suggest that Rheumazin can be a good choice for third molar removal treatment.